Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07393659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

Study acronym: PATH
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 8 months later Dec 30, 2030 → Sep 14, 2032
See other at-risk trials from ViiV Healthcare

Record History

  1. Primary and study completion pushed from Dec 30, 2030 to Sep 14, 2032 Recruitment opened · Trial sites expanded: 0 → 4 locations · Enrollment target: 183 to 181 · 2 morev2 Show 5 more changesShow less
    • Recruitment opened
    • Trial sites expanded: 0 → 4 locations
    • Enrollment target: 183 to 181
    • Start date changed from estimate of May 8, 2026 to Jul 21, 2026
    • Eligibility criteria shortened, about 29 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
Trial Details
NCT Number NCT07393659
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 181 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov